Elsevier

Drug and Alcohol Dependence

Volume 190, 1 September 2018, Pages 170-178
Drug and Alcohol Dependence

Full length article
Treatment outcome disparities for opioid users: Are there racial and ethnic differences in treatment completion across large US metropolitan areas?

https://doi.org/10.1016/j.drugalcdep.2018.06.006Get rights and content

Highlights

  • Ethnic/racial treatment completion disparities found in largest US metropolitan statistical areas (MSAs).

  • 28% of opioid users in largest US metropolitan areas completed treatment.

  • Only 3 of 42 metropolitan areas had disparities.

  • New York MSA had higher treatment completion rates and disparities vs. other MSAs.

  • Important to examine geographic variation in treatment outcomes with national data.

Abstract

Background

The present study examined racial/ethnic disparities in initial treatment episode completion for adult clients reporting opioids as their primary problem substance in large US metropolitan areas.

Methods

Data were extracted from the 2013 TEDS-D dataset (Treatment Episode Dataset-Discharge) for the 42 largest US metropolitan statistical areas (MSAs). Fixed effects logistic regression controlling for MSA was used to estimate the effect of race/ethnicity on the likelihood of treatment completion. The model was repeated for each individual MSA in a stratified design to compare the geographic variation in racial/ethnic disparities, controlling for gender, age, education, employment, living arrangement, treatment setting, medication-assisted treatment, referral source, route of administration, and number of substances used at admission.

Results

Only 28% of clients completed treatment, and the results from the fixed effects model indicate that blacks and Hispanics are less likely to complete treatment compared to whites. However, the stratified analysis of individual MSAs found only three of the 42 MSAs had racial/ethnic disparities in treatment completion, with the New York City (NYC) MSA largely responsible for the disparities in the combined sample. Supplementary analyses suggest that there are greater differences between whites and minority clients in the NYC MSA vs. other cities on characteristics associated with treatment completion (e.g., residential treatment setting).

Conclusion

This study underscores the need for improving treatment retention for all opioid using clients in large metropolitan areas in the US, particularly for minority clients in those localities where disparities exist, and for better understanding the geographic context for treatment outcomes.

Introduction

Illicit opioid use represents one of the most harmful drug problems globally, responsible for an estimated 70% of the world’s burden of disease attributable to drug use disorders as well as 66% of the 63,632 US drug overdose deaths in 2016 (Seth et al., 2018; United Nations Office on Drugs and Crime (UNODC, 2017). Although the US is the global leader in both absolute numbers (one quarter of the world’s total) and rates of overdose deaths, other nations such as Canada, Australia, Ireland, Turkey, England, Wales, and Scotland have all seen recent substantial increases in overdose mortality, primarily due to opioids (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2017a; United Nations Office on Drugs and Crime (UNODC, 2017). An important pillar for policy strategies to address the current opioid overdose crisis has been to provide increased access and capacity for treatment for those with opioid use disorders (OUDs) (Evans and Farrelly, 2017; Franklin et al., 2015; Murphy et al., 2016). One of the most widely used proximal measures of treatment effectiveness for substance use disorders (SUDs) is treatment completion (Brorson et al., 2013), generally defined as successfully completing treatment goals (Greenfield et al., 2007). Despite evidence showing sustained recovery may involve multiple episodes over time (Guerrero, 2013; McKay and Weiss, 2001), individual treatment completion episodes can serve as an important indicator associated with longer term abstinence, fewer relapses, higher levels of employment, higher wages, fewer readmissions, less future criminal involvement, and better health (Brorson et al., 2013).

Black and Hispanic people in the US tend to have lower treatment utilization rates, greater barriers to receiving treatment, and poorer outcomes, including treatment completion, compared to white clients (Alegría et al., 2006, 2011; Arndt et al., 2013; Guerrero et al., 2013a; National Research Council, 2003; Saloner and Le Cook, 2013). Similarly, in Europe, there has been a recent recognition that ethnic minorities, migrants, refugees, and asylum seekers who have substance use problems may be particularly vulnerable to barriers in accessing needed treatment services (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2017b). Evidence suggests that race/ethnicity also interacts with other factors, such as drug of choice and treatment modality, to produce disparities in treatment completion (Mennis and Stahler, 2016; Stahler et al., 2016), and these differences in outcomes vary considerably across different areas of the country (Arndt et al., 2013; Cummings et al., 2011; Guerrero et al., 2013a). The use of aggregate national level data may therefore mask geographic variations that may have important implications for SUD treatment policies that are generally implemented at the regional or municipal level in the US. This is particularly important when examining treatment outcomes for OUDs because of geographic variations in demographic characteristics, prevalence, overdose incidence, treatment systems, illicit opioid availability, and insurance coverage that exist in the US (Cummings et al., 2014; Hand et al., 2017; Martins et al., 2017; Rossen et al., 2014; Substance Abuse and Mental Health Services Administration (SAMHSA, 2017). Even in nations with more centralized national treatment systems, geographic variations in prevalence patterns and treatment access may be substantial (Morley et al., 2017; United Nations Office on Drugs and Crime (UNODC, 2017). While epidemiologic research has found important geographic and demographic differences in patterns of opioid use cross nationally (United Nations Office on Drugs and Crime (UNODC, 2017), among rural and urban users (Rigg and Monnat, 2015), across regions (Hand et al., 2017; Martins et al., 2017), and across different metropolitan areas (Roberts et al., 2010), few studies have focused on the geographic variation in racial/ethnic treatment outcome disparities (Arndt et al., 2013).

The present study examined racial and ethnic disparities in successfully completed treatment episodes for first time adult clients reporting opioids as a primary substance of use across the largest US metropolitan areas (populations greater than one million) using data extracted from the 2013 Treatment Episode Dataset-Discharge (TEDS-D) (Substance Abuse and Mental Health Services Administration (SAMHSA, 2015). We limited our sample to large metropolitan areas because there are considerable differences between urban and rural drug use patterns, treatment systems, and demographic characteristics, especially regarding opioid use (Wang et al., 2013). In addition, there are particularly large concentrations of minority groups in the largest metropolitan areas, and many smaller metropolitan areas have few OUD treatment discharges for certain racial/ethnic groups in the TEDS-D dataset, limiting statistical analyses for these areas.

Our major research questions were: (1) Are there racial/ethnic disparities in first time treatment episode completion for clients reporting opioid use as their primary substance of use in large metropolitan areas in the US? Based on prior research demonstrating racial/ethnic disparities (e.g., Guerrero et al., 2013a, b; Mennis and Stahler, 2016), we hypothesize that black and Hispanic opioid users will have a lower likelihood of treatment completion compared to whites. (2) If there are racial/ethnic disparities in first time treatment episode completion for clients reporting opioid use as their primary substance of use, do these disparities vary across large metropolitan areas in the US? Based on prior research showing geographic variation in disparities in treatment completion (Arndt et al., 2013; Saloner et al., 2014), we hypothesize that metropolitan areas will vary significantly in their level of racial/ethnic disparity.

Section snippets

Data source and sample

The data used for this study were extracted from the 2013 TEDS-D dataset (Substance Abuse and Mental Health Services Administration (SAMHSA, 2015). This dataset is compiled from an annual survey conducted by the federal government of state agencies concerning SUD treatment programs. It includes most publicly funded treatment admissions in the US during a given year and is considered generally representative of a national sample (Substance Abuse and Mental Health Services Administration (SAMHSA,

Sample characteristics

Table 1 displays the descriptive statistics for the outcome and explanatory variables. For the total sample of 34,380 discharges, only 27.8% completed treatment. The majority of the sample (70%) was white, with the remainder almost exclusively comprised of black (14%) and Hispanic (12%) people. About one quarter of the sample had less than a high school education (28%), most were not employed (79%), two thirds (69%) lived in independent housing, and the majority received treatment in outpatient

Discussion

To the best of our knowledge, this is the first analysis to examine racial/ethnic disparities in treatment episode completion for opioid using clients across and within the largest US metropolitan areas. Our results concerning racial/ethnic disparities in OUD treatment completion is consistent with a large body of research that has examined national level SUD treatment completion data (Arndt et al., 2013; Mennis and Stahler, 2016; Saloner et al., 2014; Stahler et al., 2016) as well as regional

Conclusion

As the opioid overdose crisis continues to impact people across the ethnic and racial spectrum in the US, it is important to better understand disparities in treatment outcomes. While large scale national data sets serve an important function in providing public health policymakers with information about national trends, our results suggest that there are important geographic variations in patterns of SUD treatment outcomes. In treatment systems with high levels of ethnic/racial outcome

Role of the funding source

Nothing declared.

Contributors

Both authors contributed to the conception and design of the study. Stahler drafted the Introduction and Discussion sections, and parts of the Methods and Results sections. Mennis developed the analytic plan, was responsible for analyzing the data, and drafted parts of the Methods and Results sections. Both authors read and approved the final manuscript.

Conflict of interest

No conflict declared.

Acknowledgements

The authors wish to thank Andrew Rosenblum, Noa Krawczyk, and Stephen Magura for sharing pre-publication drafts of their own papers and helpful discussion related to the findings of this study.

References (60)

  • J.R. McKay

    Continuing care research: what we have learned and where we are going

    J. Subst. Abuse Treat.

    (2009)
  • J. Mennis et al.

    Racial and ethnic disparities in outpatient substance use disorder treatment episode completion for different substances

    J. Subst. Abuse Treat.

    (2016)
  • K. Morley et al.

    Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence

    J. Subst. Abuse Treat.

    (2017)
  • K.K. Rigg et al.

    Urban vs. rural differences in prescription opioid misuse among adults in the United States: informing region specific drug policies and interventions

    Int. J. Drug Policy

    (2015)
  • E.T. Roberts et al.

    Environmental conditions, political economy, and rates of injection drug use in large US metropolitan areas 1992–2002

    Drug Alcohol Depend.

    (2010)
  • L.M. Rossen et al.

    Hot spots in mortality from drug poisoning in the United States, 2007–2009

    Health Place

    (2014)
  • E. Sahker et al.

    Evaluating racial disparity in referral source and successful completion of substance abuse treatment

    Addict. Behav.

    (2015)
  • B. Saloner et al.

    Explaining racial/ethnic differences in adolescent substance abuse treatment completion in the United States: a decomposition analysis

    J. Adolesc. Health

    (2014)
  • G. Stahler et al.

    The effect of individual, program, and neighborhood variables on continuity of treatment among dually diagnosed individuals

    Drug Alcohol Depend.

    (2007)
  • G.J. Stahler et al.

    Residential and outpatient treatment completion for substance use disorders in the U.S.: Moderation analysis by demographics and drug of choice

    Addict. Behav.

    (2016)
  • K.H. Wang et al.

    Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents

    Drug Alcohol Depend.

    (2013)
  • M. Alegría et al.

    Improving drug treatment services for Hispanics: research gaps and scientific opportunities

    Drug Alcohol Depend.

    (2006)
  • R.L. Cooper et al.

    Racial differences in retention in residential substance abuse treatment: the impact on African American men

    Res. Soc. Work Pract.

    (2010)
  • J.R. Cummings et al.

    Race/ethnicity and geographic access to medicaid substance use disorder treatment facilities in the United States

    JAMA Psychiatry

    (2014)
  • M.L. Dennis et al.

    Managing addiction as a chronic condition

    Addict. Sci. Clin. Pract.

    (2007)
  • Drug Enforcement Administration (DEA)

    2017 National Drug Threat Assessment Summary. DEA-DCT-DIR-040-17. [WWW Document]

    (2017)
  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

    Drugs Policy and the City in Europe. [WWW Document

    (2015)
  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

    European Drug Report: Trends and Developments. [WWW Document]

    (2017)
  • European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

    Health and Social Responses to Drug Problems: A European Guide. [WWW Document]

    (2017)
  • A. Evans et al.

    The Mayor’s Task Force to Combat the Opioid Epidemic in Philadelphia: Final Report and Recommendations. [WWW Document]

    (2017)
  • Cited by (51)

    View all citing articles on Scopus
    View full text